ClinicalTrials.gg
Active, not recruitingNCT06280079LIPCAL-ALS IIUpdated Oct 13, 2026

Ultra-high-caloric, Fatty Diet in ALS

An interventional study of Ultra-high-caloric fatty diet and Placebo in Amyotrophic Lateral Sclerosis, sponsored by University of Ulm. Active, not recruiting at 23 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by University of Ulm · Not applicable, Interventional, and Treatment

How we know

Updated Oct 13, 2026Now Active, not recruitingStart date moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
399
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 76 studies in Amyotrophic Lateral Sclerosis with a site in Germany — 17 open to participants now, 26 under way, 6 of them phase 3. Amyotrophic Lateral Sclerosis · Germany.

Enrollment
14th of 63
399 · median 219
Started
2024
with 5 others
No phase
6 of 76
2 open now
Primary completion
2028-04
later than 18 of 25 live
Registered
62nd of 76
by date
Lead sponsor
7 of 76
University of Ulm

Among the 76 studies in Amyotrophic Lateral Sclerosis with a site in Germany, this one is the 14th largest by enrollment of the 63 interventional ones that give a count, is one of 6 that started in 2024, is one of 6 with no phase, reaches primary completion later than 18 of the 25 other live ones, and was the 62nd registered.

Amyotrophic Lateral Sclerosis

981 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 280 are open to participants now.

Browse Amyotrophic Lateral Sclerosis studies →

Open to participants now

17 of the 76 studies in Amyotrophic Lateral Sclerosis with a site in Germany are open now. Recruiting first, the newest first:

12 more — sign in →

All 17 open studies →

A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →

Who these studies take

Of the 194 Amyotrophic Lateral Sclerosis studies recruiting now, 119 (61%) set no upper age limit and 23 (12%) stop at 75 or younger; 15 take children under 18; 56 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 76 studies in Amyotrophic Lateral Sclerosis with a site in Germany, or all of them as a file.
02

Study summary

This study aims at evaluating efficacy and tolerability of an ultra-high-caloric, fatty diet (UFD) compared to placebo in patients with amyotrophic lateral sclerosis (ALS).

Read the detailed description

ALS is a fatal neurodegenerative disease, leading to progressive paralysis of voluntarily innervated muscles and to death caused by respiratory failure after a mean disease duration of 2-4 years.The proposed study aims at improving survival of ALS patients by targeting metabolic parameters. ALS patients feature an intrinsic hypermetabolism as signified by an increased resting energy expenditure, which significantly contributes to progressive weight loss and cachexia. The extent of weight loss is an independent prognostic factor for survival in ALS. It has been shown that survival of ALS mice can be prolonged by applying a high-caloric nutrition. Furthermore, ALS patients feature distinct alterations of lipid metabolism, and various studies suggest a protective effect of high triglyceride serum levels.

In the precursor-study LIPCAL-ALS-I, a randomized, placebo-controlled, multicenter trial, evaluating the effects of a high-caloric fatty diet (HCFD), the primary endpoint (survival in the whole study population) was missed. However, post-hoc analysis revealed showed that HCFD (1) increased survival and reduced weight loss in normal to fast-progressing patients (patients with a functional decline measured by ALS Functional Rating Scale Revised) above the median at baseline; p=0.02), (2) slowed down functional decline (measured by Amyotrophic Lateral Sclerosis Functional Rating Scale Revised) in the whole study population (p\<0.0125), and (3) lowered neurofilament light chain (NfL) serum levels as a prognostic biomarker in the whole study population (p=0.0225).

Therefore, this study aims at prolonging survival in ALS patients by applying 1.5-fold dosage of the same intervention as in LIPCAL-ALS I in a larger number of patients, excluding patients with slow disease progression.

03

Conditions studied

  • Amyotrophic Lateral Sclerosis

Keywords

  • Amyotrophic Lateral Sclerosis
  • High-caloric, high-fat nutrition
  • Survival
  • Randomized controlled trial
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Possible, probable (clinically or laboratory supported) or definite amyotrophic lateral sclerosis according to the revised version of the El Escorial criteria
  • Disease duration (onset of first paresis or bulbar symptoms) \< 24 months
  • Loss of amyotrophic lateral sclerosis functional rating scale revised of ≥ 0.33 points/month based on the formula: (48 - myotrophic lateral sclerosis functional rating scale revised score at screening visit) / (months between onset and screening visit)
  • Age ≥18 years.
  • Either continuously treated with a stable dose of riluzole, OR not treated with riluzole for the last 4 weeks prior to inclusion
  • Either continuously treated with a stable dose of edaravone, OR not treated with edaravone for the last 4 weeks prior to inclusion
  • Either continuously treated with a stable dose of sodium-phenylbutyrate/taurursodiol, OR not treated with sodium-phenylbutyrate/taurursodiol for the last 4 weeks prior to inclusion
  • Capable of thoroughly understanding all information given
  • full written according to good clinical practice

Exclusion criteria

Exclusion Criteria:

  • Previous participation in another interventional study involving an active treatment within the preceding 4 weeks
  • Tracheostomy or continuous permanent ventilator dependence (>22 hours per day)
  • Pregnancy or breastfeeding
  • Any medical condition known to have an association with motor neuron dysfunction which might confound or obscure the diagnosis of ALS
  • Presence of any concomitant life-threatening disease or impairment likely to interfere with functional assessment.
  • Evidence of a major psychiatric disorder or clinically evident dementia precluding evaluation of symptoms.
  • Liable to be not cooperative or comply with study requirements as assessed by the investigator, or unable to be reached in the case of emergency
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
399 participants (actual)

Study arms

  • Experimental
    Ultra-high-caloric fatty diet

    ultra-high-caloric, high-fat, fluid nutritional supplement oral intake of 4 times 35 ml per day in addition to normal food intake, corresponding to +630 kcal and +70g fat per day

    Dietary Supplement: Ultra-high-caloric fatty diet

  • Placebo comparator
    Placebo

    placebo, fluid nutritional supplement oral intake of 4 times 35 ml per day in addition to normal food intake, corresponding to +50 kcal and +3,5g fat per day

    Other: Placebo

Interventions

  • Dietary supplementUltra-high-caloric fatty diet

    100% fat (70g), saturated fatty acids 7,5g, monounsaturated fatty acids 42,6g, polyunsaturated fatty acids 19,9g, long-chain fatty acids 100%, ratio omega-6 to omega-3 fatty acids 5:1, protein 0g, carbohydrates 0g, fiber 0g

  • OtherPlacebo

    \<5% fat (\<3,5g), protein 0g, carbohydrates 0g, fiber 0g

06

What researchers measure

Primary outcomes

  1. Survival

    Time from date of randomization until date of death, tracheostomy, or permanent continous ventilation (\>22 hours per day)

    Time frame: 18 months

Secondary outcomes

  1. Amyotrophic Lateral Sclerosis Functional Rating Scale Revised

    Change per month of Amyotrophic Lateral Sclerosis Functional Rating Scale Revised

    Time frame: 18 months

  2. Rasch Overall Amyotrophic Lateral Sclerosis Disability Scale

    Change per month of Rasch Overall Amyotrophic Lateral Sclerosis Disability Scale

    Time frame: 18 months

  3. Individual Quality of Life

    Change of Euro Quality of Life 5D 5L (EQ-5D-5L) compared to baseline

    Time frame: 18 months

  4. Slow vital capacity

    Change of slow vital capacity compared to baseline

    Time frame: 18 months

  5. Survival

    Time from date of randomization until date of death, tracheostomy, or permanent continous ventilation (\>22 hours per day)

    Time frame: 6 months

  6. Survival

    Time from date of randomization until date of death, tracheostomy, or permanent continous ventilation (\>22 hours per day)

    Time frame: 12 months

  7. Time to death

    Time from date of randomization until date of death

    Time frame: 18 months

  8. Time to tracheostomy

    Time from date of randomization until date of tracheostomy

    Time frame: 18 months

  9. Time to permanent continous ventilator dependence

    Time from date of randomization to permanent continous ventilator dependence (\>22 hours per day)

    Time frame: 18 month

  10. Ventilation assistance-free survival

    Time from date of randomization until implementation of mechanical ventilation

    Time frame: 18 months

  11. Body Mass Index

    Change of body mass index compared to baseline

    Time frame: 18 months

  12. Council of Nutrition Appetite Questionnaire

    Change of Council of Nutrition Appetite Questionnaire sum score compared to baseline

    Time frame: 18 months

  13. Eating Habits

    Change of Ulm Nutrition Questionnaire compared to baseline; qualitative changes on a descriptional level (the questionnaire has no sum score); the score is meant to detect changes of eating habits and has been used in the precursor study LIPCAL-ALS I (see doi: 10.1002/ana.25661).

    Time frame: 18 months

  14. Neurofilament light chain

    Change of neurofilament light chain serum levels compared to baseline

    Time frame: 18 months

  15. Amyotrophic Lateral Sclerosis Functional Rating Scale Revised Prediction Model

    Difference between observed and predicted decrease of Amyotrophic Lateral Sclerosis Functional Rating Scale Revised (measured as points lost per month), based on the a prediction model, which estimates disease progression based on neurofilament light chain serum baseline levels

    Time frame: 18 months

  16. Neurofilament Assess Score

    Difference between observed and predicted survival based on the Neurofilament Assess Score, a score estimating survival based on the neurofilament light chain serum baseline levels

    Time frame: 18 months

Other outcomes

  1. Microtubule-associated protein 2 in serum

    change of Microtubule-associated protein 2 levels in serum compared to baseline

    Time frame: 18 months

  2. Microtubule-associated protein 2 in cerebrospinal fluid

    change of microtubule-associated protein 2 levels in cerebrospinal fluid compared to baseline

    Time frame: 18 months

  3. Ubiquitin carboxy-terminal hydrolase L1 in serum

    change of ubiquitin carboxy-terminal hydrolase L1 levels in serum compared to baseline

    Time frame: 18 months

  4. Ubiquitin carboxy-terminal hydrolase L1 in cerebrospinal fluid

    change of ubiquitin carboxy-terminal hydrolase L1 levels in cerebrospinal fluid compared to baseline

    Time frame: 18 months

  5. Transmembrane glycoprotein NMB in serum

    change of transmembrane glycoprotein NMB levels in serum compared to baseline

    Time frame: 18 months

  6. Transmembrane glycoprotein NMB in cerebrospinal fluid

    change of transmembrane glycoprotein NMB levels in cerebrospinal fluid compared to baseline

    Time frame: 18 months

  7. Human cartilage glycoprotein 39 in serum

    change of human cartilage glycoprotein 39 levels in serum compared to baseline

    Time frame: 18 months

  8. Human cartilage glycoprotein 39 in cerebrospinal fluid

    change of human cartilage glycoprotein 39 levels in cerebrospinal fluid compared to baseline

    Time frame: 18 months

  9. SNAP-25 in serum

    change of SNAP-25 levels in serum compared to baseline

    Time frame: 18 months

  10. SNAP-25 in cerebrospinal fluid

    change of SNAP-25 levels in cerebrospinal fluid compared to baseline

    Time frame: 18 months

  11. Beta-synuclein in serum

    change of beta-synuclein levels in serum compared to baseline

    Time frame: 18 months

  12. Beta-synuclein in cerebrospinal fluid

    change of beta-synuclein levels in cerebrospinal fluid compared to baseline

    Time frame: 18 months

  13. Aquaporin-4 in serum

    change of aquaporin-4 levels in serum compared to baseline

    Time frame: 18 months

  14. Aquaporin-4 in cerebrospinal fluid

    change of aquaporin-4 levels in cerebrospinal fluid compared to baseline

    Time frame: 18 months

  15. Glial fibrillary acidic protein in serum

    change of glial fibrillary acidic protein levels in serum compared to baseline

    Time frame: 12 months

  16. Glial fibrillary acidic protein in cerebrospinal fluid

    change of glial fibrillary acidic protein levels in cerebrospinal fluid compared to baseline

    Time frame: 12 months

  17. Soluble triggering receptor expressed on myeloid cell-1 in serum

    change of soluble triggering receptor expressed on myeloid cell-1 levels in serum compared to baseline

    Time frame: 12 months

  18. Soluble triggering receptor expressed on myeloid cell-1 in cerebrospinal fluid

    change of soluble triggering receptor expressed on myeloid cell-1 levels in cerebrospinal fluid compared to baseline

    Time frame: 12 months

  19. CC-chemokine ligand 2 in serum

    change of CC-chemokine ligand 2 levels in serum compared to baseline

    Time frame: 12 months

  20. CC-chemokine ligand 2 in cerebrospinal fluid

    change of CC-chemokine ligand 2 levels in cerebrospinal fluid compared to baseline

    Time frame: 12 months

  21. interleukin-1b in serum

    change of interleukin-1b levels in serum compared to baseline

    Time frame: 12 months

  22. interleukin-1b in cerebrospinal fluid

    change of interleukin-1b levels in cerebrospinal fluid compared to baseline

    Time frame: 12 months

  23. interleukin-2 in serum

    change of interleukin-2 levels in serum compared to baseline

    Time frame: 12 months

  24. interleukin-2 in cerebrospinal fluid

    change of interleukin-2 levels in cerebrospinal fluid compared to baseline

    Time frame: 12 months

  25. interleukin-4 in serum

    change of interleukin-4 levels in serum compared to baseline

    Time frame: 12 months

  26. interleukin-4 in cerebrospinal fluid

    change of interleukin-4 levels in cerebrospinal fluid compared to baseline

    Time frame: 12 months

  27. interleukin-6 in serum

    change of interleukin-6 levels in serum compared to baseline

    Time frame: 12 months

  28. interleukin-6 in cerebrospinal fluid

    change of interleukin-6 levels in cerebrospinal fluid compared to baseline

    Time frame: 12 months

  29. interleukin-10 in serum

    change of interleukin-10 levels in serum compared to baseline

    Time frame: 12 months

  30. interleukin-10 in cerebrospinal fluid

    change of interleukin-10 levels in cerebrospinal fluid compared to baseline

    Time frame: 12 months

  31. interleukin-12p70 in serum

    change of interleukin-12p70 levels in serum compared to baseline

    Time frame: 12 months

  32. interleukin-12p70 in cerebrospinal fluid

    change of interleukin-12p70 levels in cerebrospinal fluid compared to baseline

    Time frame: 12 months

  33. interleukin-17 in serum

    change of interleukin-17 levels in serum compared to baseline

    Time frame: 12 months

  34. interleukin-17 in cerebrospinal fluid

    change of interleukin-17 levels in cerebrospinal fluid compared to baseline

    Time frame: 12 months

  35. Tumor necrosis factor alpha in serum

    change of tumor necrosis factor alpha levels in serum compared to baseline

    Time frame: 12 months

  36. Tumor necrosis factor alpha in cerebrospinal fluid

    change of tumor necrosis factor alpha levels in cerebrospinal fluid compared to baseline

    Time frame: 12 months

07

Study locations

23 sites
08

References and documents

Individual participant data

Plan to share: Yes — Individual participant data that underlie the results reported in this article, after de-identification (text, tables, and figures) as well as the study protocol will be available.

Supporting information: Study protocol

Time frame: Data will be available beginning 3 months and ending 5 years following article publication.

Access criteria: Data will be shared with researchers who provide a methodologically sound proposal. Data will be shared for analyses to achieve the aims in the approved proposal.

Data sharing details ↗ · www.uniklinik-ulm.de

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2024 (actual). Primary completion is estimated for Apr 2028, 45 months after the start.

Of 134 non-industry interventional studies with no phase under Amyotrophic Lateral Sclerosis, half reached primary completion within 40 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 60. This study's planned 45 months is above that.

Counting every sponsor, half of 154 studies reached it within 35 months; a quarter within 23 and three quarters within 60.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 13, 2026: start Jun 2024 → Jul 2024, primary completion Jan 2028 → Apr 2028 and completion Jan 2028 → Apr 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 19, 2024
First posted
Feb 28, 2024
StartActual
Jul 2, 2024was Jun 2024
Primary completionEst.
Apr 5, 2028was Jan 2028
CompletionEst.
Apr 5, 2028was Jan 2028
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 13, 2026
Start date
Jun 1, 2024→Jul 2, 2024
Oct 13, 2026
Primary completion
Jan 1, 2028→Apr 5, 2028
Oct 13, 2026
Study completion
Jan 1, 2028→Apr 5, 2028
Oct 13, 2026
Enrollment
392 (estimated)→399 (actual)
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    Recruiting→Active, not recruiting
    Start date Jun 1, 2024→Jul 2, 2024
    Primary completion Jan 1, 2028→Apr 5, 2028
    Study completion Jan 1, 2028→Apr 5, 2028
    Enrollment 392 (estimated)→399 (actual)
    + 4 other changes: identifiers, verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06280079
Lead sponsor
University of Ulm
Responsible party
Albert Christian Ludolph, Prof. (Prof. Dr., University of Ulm) — Principal investigator
First posted
Feb 28, 2024
Start date
Jul 2, 2024
Primary completion
Apr 5, 2028 (estimated)
Completion
Apr 5, 2028 (estimated)
Last update
Oct 13, 2026

Study contacts

Johannes Dorst, Prof. Dr.
principal investigator · University of Ulm

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion